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Phenotypic characteristics of early Wolfram
syndrome
Bess A Marshall1,15*, M Alan Permutt2ˆ, Alexander R Paciorkowski3,4,5, James Hoekel1,6,14, Roanne Karzon7,8,14,
Jon Wasson2, Amy Viehover1,9, Neil H White1,2,14, Joshua S Shimony10, Linda Manwaring1, Paul Austin11,12,
Timothy E Hullar7, Tamara Hershey9,10,13 and the Washington University Wolfram Study Group
Abstract
Background: Wolfram Syndrome (WFS:OMIM 222300) is an autosomal recessive, progressive, neurologic and
endocrinologic degenerative disorder caused by mutations in the WFS1 gene, encoding the endoplasmic reticulum
(ER) protein wolframin, thought to be involved in the regulation of ER stress. This paper reports a cross section of
data from the Washington University WFS Research Clinic, a longitudinal study to collect detailed phenotypic data
on a group of young subjects in preparation for studies of therapeutic interventions.
Methods: Eighteen subjects (ages 5.9–25.8, mean 14.2 years) with genetically confirmed WFS were identified
through the Washington University International Wolfram Registry. Examinations included: general medical,
neurologic, ophthalmologic, audiologic, vestibular, and urologic exams, cognitive testing and neuroimaging.
Results: Seventeen (94%) had diabetes mellitus with the average age of diabetes onset of 6.3 ± 3.5 years. Diabetes
insipidus was diagnosed in 13 (72%) at an average age of 10.6 ± 3.3 years. Seventeen (94%) had optic disc pallor
and defects in color vision, 14 (78%) had hearing loss and 13 (72%) had olfactory defects, eight (44%) had impaired
vibration sensation. Enuresis was reported by four (22%) and nocturia by three (17%). Of the 11 tested for bladder
emptying, five (45%) had elevated post-void residual bladder volume.
Conclusions: WFS causes multiple endocrine and neurologic deficits detectable on exam, even early in the course
of the disease. Defects in olfaction have been underappreciated. The proposed mechanism of these deficits in WFS
is ER stress-induced damage to neuronal and hormone-producing cells. This group of subjects with detailed clinical
phenotyping provides a pool for testing proposed treatments for ER stress. Longitudinal follow-up is necessary for
establishing the natural history and identifying potential biomarkers of progression.
Keywords: Diabetes mellitus, DIDMOAD, Diabetes insipidus, Hearing loss, Optic atrophy, Color blindness,
Neurodegenerative disorder
Background
Wolfram syndrome (WFS) (OMIM #222300) is a rare
autosomal recessive genetic disease characterized by insu-
lin dependent diabetes mellitus, optic atrophy, blindness,
hearing loss, and other neurological dysfunctions resulting
in death from widespread neurodegeneration in the third
or fourth decade [1]. The causative gene (WFS1) [2],
which encodes the wolframin protein, has been identified,
and a number of loss-of-function mutations have been de-
scribed [2,3]. Cell [4] and animal models [5] have led to
the discovery that the wolframin protein resides in the
endoplasmic reticulum (ER) membrane [6], and that
mutant forms predispose insulin-producing pancreatic
β-cells to ER stress-mediated apoptosis [7-9]. Both type
1 and type 2 diabetes have been shown to result from a
variety of genetic risk factors and environmental com-
ponents. These factors impinge on pancreatic β-cells
resulting in ER stress, oxidative stress, impaired signal
transduction, and mitochondrial dysfunction, all com-
bining to result in β-cell apoptosis and diabetes[10-13].
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The complexity of type 1 and type 2 diabetes makes it
difficult to discern the contribution of any one gene or
pathogenic mechanism. In contrast to the multifactorial
etiology of diabetes, subjects with WFS represent an
early-onset form of diabetes and neurodegeneration due
to deficiency of a single protein, making WFS an ideal
model of an ER stress disorder. Currently, no interven-
tion is known to alter the progression or life expectancy
in WFS, but earlier recognition of the syndrome in indi-
viduals could improve their quality of life by allowing
earlier intervention for the various debilitating compo-
nents of WFS.
While there are numerous reports of the features of
WFS from retrospective records [1,3,14-18], there are
no direct, detailed clinical observations of a young co-
hort studied in one center by the same observers. This
study represents a cross-sectional analysis of a group of
subjects relatively early in the disease with varying dur-
ation and manifestations of the syndrome. The ultimate
objective of this study is to observe subjects with WFS
longitudinally beginning early in the disease and to
identify appropriate biomarkers for monitoring disease
progression, thus preparing for future clinical trials.
We report the detailed clinical phenotype of a group of
WFS subjects seen at our annual multidisciplinary




Eighteen participants, 3 of whom were siblings, aged 5 to
25 were recruited through the Washington University
Wolfram Syndrome International Registry website (http://
wolframsyndrome.dom.wustl.edu/medical-research/Wolfram-
Syndrome-Home.aspx) to participate in standardized eval-
uations across domains known to be associated with WFS.
In most cases, subjects initiated joining the registry and
so were self-selected and the investigators further se-
lected those who were young and in the early stages of
the syndrome to take part in the research clinic.
Inclusion criteria for the registry are the diagnosis of
insulin-dependent diabetes mellitus and optic atrophy
by a physician before 18 years of age and/or genetic
confirmation of a WFS1 mutation. Subjects are ex-
cluded from the registry if they or a guardian are unable
to speak English or to obtain help with translation and
thus are unable to understand the registry question-
naires. The clinic protocol was approved in advance by
the Washington University Human Research Protection
Office and all subjects provided informed consent if
adults and assent with consent by parents if minor chil-
dren. Subject’s identification numbers shown in this re-
port are based on their numbers in the registry and are
therefore not necessarily consecutive.
Methods
Overview
All subjects attended the Washington University WFS
Research Clinic in St. Louis, MO, in August 2010, July
2011, and/or July 2012. This report includes data from
each subject’s initial evaluation. All subjects had a
complete medical and family history and a physical
examination (including a mixed meal challenge test) by
a pediatric endocrinologist (BM or NHW); a neurologic
history and complete neurologic exam by a pediatric
neurologist (AP and AV); visual acuity, refraction, as-
sessment of nystagmus, color vision testing, pupillary
testing and dilated fundus exams by a pediatric optom-
etrist (JH); audiology exams supervised by an audiologist
(RK); complete family history by a genetic counselor
(LM); vestibular examination by an neurotolologist
(TEH); urologic evaluation by a pediatric urologist (PA)
and neuroimaging supervised by a pediatric neuroradiol-
ogist (JS), and psychological, and cognitive testing super-
vised by a neuropsychologist (TH).
Specific tests
Mixed meal challenge tests All subjects but one had
diabetes mellitus and all diabetic subjects were taking in-
sulin either by multiple daily injections (Lantus and a
rapid-acting insulin analog) or by insulin pump. The
night before the oral mixed meal tolerance test, the sub-
jects turned their pump basal rate to 50% of the normal
rate at midnight or took half of their evening dose of
Lantus insulin and fasted from midnight until the test at
8 a.m. The mixed meal consisted of 6 ml/kg (maximum
360 ml) of Boost. Blood for glucose and C-peptide meas-
urement was drawn at time 0 (fasting) and 30 minutes
after the Boost. If a subject’s fasting glucose exceeded
11.1 mmol/l, the test was not performed, but fasting glu-
cose and C-peptide were obtained.
Audiology and vestibular testing Pure tone testing
(250 to 8,000 Hz) was administered via insert earphones
with a Madsen Orbiter 922 audiometer calibrated to
American National Standards Institute [ANSI] S3.6-1996
[19]. WU.WOLF-05 and WU.WOLF-12 were not tested
at the multidisciplinary clinic; audiologic data were
obtained from their local audiologist. To test vestibular
function, harmonic sinusoidal rotations about the earth-
vertical axis were administered to 8 subjects over the
frequency range of 0.025 to 0.5 Hz at a peak velocity of
60 deg/sec using a clinical rotational chair and video eye
movement-recording device (Micromedical Technolo-
gies, Chatham, IL). All subjects were tested only with
low-amplitude rotational stimulation; this is not sensitive
to all vestibular losses.
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Neuroimaging MRI scans were acquired in the Center
for Clinical Imaging Research on a Siemens 3 T Tim
Trio Magnetic Resonance Imaging (MRI) scanner. Blood
glucose was confirmed to be above 4 mmol/l prior to
scanning. T1-weighted (sagittal acquisition, TR = 2,400,
TE = 3.16, TI = 1,000, voxel res = 1 × 1 × 1 mm, frames =
176, Flip = 8, Time = 8:09) and T2 FLAIR images (trans-
verse acquisition, TR = 9,190, TE = 98, TI = 2,500, voxel
res = .86 × .86 × 3 mm, frames = 42, Flip = 150, Time =
3:59) were read by a pediatric neuroradiologist. The
evaluation of the pituitary bright spot was performed
qualitatively by a pediatric neuroradiologist with over
10 years of experience (JSS). The initial interpretation of
the scans was done as they were acquired, however the
final evaluation of the pituitary for all subjects was
performed in one sitting in order to facilitate comparison
across the group.
Cognitive testing Blood glucose was confirmed to be
above 4 mmol/l prior to testing.
The Wechsler Abbreviated Scale of Intelligence (WASI)
[20] Vocabulary and Similarities subtasks were adminis-
tered to allow us to generate estimated verbal intelligence
quotients (IQ) by comparing to age norms.
University of Pennsylvania smell identification test
(UPSIT) [21] To test olfaction, we administered a
scratch-and-sniff test of common odorants. The UPSIT
has high reliability (test-retest r = 0.94) and established
sensitivity [21]. The UPSIT defines degrees of olfactory
sensitivity based on how many scents the subject identi-
fies correctly. Subjects can be classified as having
normosmia (for age 5–9 = 19 or more correct, for age
10–14 = 32 or more correct, for age 15 and up = 35 or
more correct for female, 34 or more correct for male),
mild microsmia (for age 10–14 = 28–31 correct, for age
15–29 = 31–34 correct for female, 30–33 correct for male),
moderate microsmia (for age 10–14 = 23–27 correct, for
age 15 and up = 26–30 correct for female, 26–29 correct
for male), severe microsmia (for age 10–14 = 19–22
correct, for age 15 and up = 19–25 correct), total anosmia
(6–18 correct), or “probable malingering” (fewer than 6
correct) based on published gender and age-adjusted
norms [22].
Results
Clinical characteristics and mutation analysis
There were 18 subjects with WFS with an average age of
14.2 ± 5.7 years at their first visit to the research clinic.
The ages of the seven male subjects ranged from 7.3 to
22.9 years (average of 13.7 ± 5.4) and the ages of the
eleven female subjects from 5.9 to 25.8 years (average of
14.7 ± 5.8). All subjects had been diagnosed with both
diabetes mellitus (DM) and optic atrophy prior to their
initial clinic visit except one, who was diagnosed with
WFS due to the presence of insulin requiring diabetes
mellitus and a family history of the condition, and one
who was diagnosed with WFS due to genetic testing
done due to findings of optic atrophy and hearing loss.
Table 1 shows the family and medical history for each
subject.
The average age of onset of DM was 6.3 ± 3.5 years for
the 17 (94%) who had DM. One female, WU.WOLF-19,
had not yet developed DM at age 11.9 years. Of the
remaining ten females, the average age of onset was 6.5 ±
4 years, but without a normal distribution: two were diag-
nosed in the third year of life, one each in the fourth, fifth,
and sixth, two in the seventh, one in the eighth, then a
skip to the 14th and 15th year of life. Of the male subjects,
the average age of onset of DM was 5.9 ± 2.7, with a simi-
lar age distribution to the females except there were no
males who did not have DM by age 10.8 years.
Turning to diabetes insipidus (DI), the average age of
onset for the entire group was 10.6 ± 3.3 years, and 13
subjects (72%) had DI. All of the males had DI with an
average age of onset of 10.5 ± 3.9 years and an age of on-
set range from 6 to 17 years. Six of the eleven female
(55%) subjects had DI, with an average age of onset of
10.7 ± 2.8 years and a range of 7.5–14.6 years. Those fe-
male subjects who did not have DI had an average age
of 13.9 ± 2.7 and a range of 10.8–15.8 years. This sug-
gests that males may have a tendency toward an earlier
onset of DI, though the number of subjects is small.
Optic atrophy was diagnosed in all but one subject
(94%). The average age of diagnosis was 8.7 ± 3.3 years
for all subjects with optic atrophy, 7.5 ± 2.4 (range 5–11)
years for the males, and 9.3 ± 3.7 (range 5–15.3) years
for the females.
Nine subjects (50%) had previously-diagnosed hearing
loss and 5 more (for a total of 78%) were newly diag-
nosed with hearing loss at the clinic. Six of the seven
male subjects had hearing loss with a mean age of diag-
nosis of 8.2 ± 2.1 (range 6–11.9) years. The one boy with
no loss still had normal hearing at age 14.3 years. The
mean age of diagnosis of hearing loss in the female sub-
jects was 9.9 years but the group again did not exhibit a
normal distribution. The standard deviation was 7.8 years
for onset of hearing loss in the female group and three
of the 11 females (27%) had no hearing loss at ages 10.9,
11.7, and 15.8 years. Of those with hearing loss, two had
profound hearing loss from very early in life—subject
WU.WOLF-05 diagnosed at age 1.7 years and subject
WU.WOLF-19 who was profoundly deaf with no lan-
guage development at the time of her adoption at age 5
(note—age 5 was used as her “official” age of hearing
loss diagnosis in the table and calculation of the average
age of onset of hearing loss as that is the youngest age
that we can be certain that she had hearing loss).
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Table 1 Subject medical and family history












FH DM* FH hearing
loss*
Other problems




WU.WOLF-02 10.9 F 6 7.5 9 N 9.5 N Mgaunt Pgf None
WU.WOLF-03 17.9 M 5.0 6 6 6 6 N Mgf mgm GERD; restless legs;
occasional myoclonus
WU.WOLF-04 23.8 F 2.3 12 5 5 12 N Father, pgm, paunts Father GERD; OCD spectrum
behaviors; constipation, loss
of taste sensation
WU.WOLF-05 13.8 F 3.8 N 12 1.7 13 N Mgf, mggm, mgaunt mcousin FTT at 1 year, feeding tube at
age 2 1/2; Near-drowning
age 6 ½; celiac sprue
WU.WOLF-07 7.3 M 2.7 7 N 7 3 Y† Mgf, paunt, puncle,
mggf, mguncle
Pgf, 3 pguncles anxiety




















loss of taste sensation
WU.WOLF-13 5.9 F 4.8 7.5 5.2 6 5.4 N first cousin N Constipation
WU.WOLF-14 13.6 F 6.3 11.3 7.9 10.1 8.8 N Mgf, pggm, mggf N None
WU.WOLF-15 10.8 F 2.8 N 7 9 7 N N brother Constipation
WU.WOLF-16 25.8 F 13.1 14.6 13.6 25.8 14.9 N pgf pgm None




WU.WOLF-18 11.9 M 5.1 10.33 10.1 11.9 10.6 N Mgf Father None
WU.WOLF-19 11.9 F N N 5 Prior to 5 11 No info No info No info International adoption age 5,





















Table 1 Subject medical and family history (Continued)
WU.WOLF-22 15.8 F 14 N 13 N 14.6 N Mggf, pgm, pgf N None
MEAN 14.2 6.3 10.6 8.7 9.0 10.3
STD 5.7 3.5 3.3 3.3 6.0 4.2
*Not in a person with Wolfram syndrome.
†3 distant cousins with Wolfram, parents consanguinous.
‡Sibling with Wolfram (patients WU.WOLF-11, WU.WOLF-10,WU.WOLF-09 are siblings).
Abbreviations: DI: diabetes insipidus; DM: diabetes mellitus; FH: family history; FTT: failure to thrive; GERD: gastroesophageal reflux disease; maunt: maternal aunt; mcousin: maternal cousin; mgaunt: maternal great
aunt; mgf: maternal grandfather; mggf: maternal great grandfather; mggm:maternal great grandmother; mgm: maternal grandmother; mguncle: maternal great uncle; muncle: maternal uncle; OCD: obsessive



















Although it is not possible to determine at what age she
developed hearing loss, anecdotal evidence suggested
that she never had functional hearing. There are two of
the female subjects who developed hearing loss late, at
ages 25.8 and 16.3 years, and the remaining group of
four developed hearing loss at an average age of 7.5 ±
2.4 years.
The majority of subjects had a family history of dia-
betes or hearing loss in relatives who are not believed to
have WFS, though none of the relatives with hearing loss
has been tested for WFS as far as we are aware besides
those noted to have WFS. Table 2 shows the mutations
in the WFS1 gene that are present in each subject. Two
subjects had mutations found in only one allele and one
of those, c.937C > T; p.H313Y, has been reported to
present in an autosomal dominant fashion in a subject
who, like this one, presented with very early profound
hearing loss [23].
History and review of systems
Only four (22%) of the subjects had a normal birth his-
tory, the others reporting meconium aspiration, preterm
labor, breech presentation, or failure to progress in labor.
All of the subjects had normal language development at
the time of the clinic. A near drowning incident in early
childhood in WU.WOLF-05 had residual neurologic ef-
fects. A history of provoked seizures (due to fever or
hypoglycemia) was found in three (17%). Significant psy-
chiatric issues were reported in two (11%), including
repetitive behaviors, obsessive compulsive disorder, and
auditory hallucinations. Constipation (seven subjects,
39%) and a loss of normal taste sensation (three subjects,
17%) were reported in several.
Diabetes mellitus
The results of the mixed meal tolerance test are shown
in Table 3. WU.WOLF-19 was not diabetic either by his-
tory, by hemoglobin A1c testing, or by glucose tolerance
testing and she had a strong C-peptide response. Two
subjects (11%) had a rise in C-peptide of greater than
0.3 ng/ml in response to the mixed meal and both of
those had been diagnosed with diabetes within the past
2 years. A measureable rise in C-peptide or a C-peptide
of 1.0 or higher at baseline was found in seven (39%) of
the subjects. The mean hemoglobin A1c was 7.7%, indi-
cating fairly good glycemic control. Only two (11%) of
subjects reported a history of diabetic ketoacidosis and
one (6%) reported a history of hypoglycemic seizures.
Neurologic and neuropsychological assessments
On exam, most subjects had some abnormal findings
(Table 4), with ten (56%) showing gait abnormalities ap-
parent on a standard detailed neurologic exam. However,
on detailed specific testing for gait and balance distur-
bances, this group of WFS subjects was found to walk
more slowly, take shorter and wider steps, and spend
more time in double support than an age matched group
of healthy control individuals (data previously published
Table 2 Mutation analysis of the WFS1 gene
Subject Allele 1 Allele 2
WU.WOLF-01 c.1060-1062delTTC; p.F354del c.2663C>A; p.S888X
WU.WOLF-02 fc.2648del4; p.F883fsX950 No mutation
WU.WOLF-03 c.1230-1233delCTCT; p.Val412fs440Stop c.1243-1245delGTC: p.Val415del
WU.WOLF-04 c.1112G>A; p.W371X c.1885C>T; p.R629W
WU.WOLF-05 c.937C>T; p.H313Y No mutation
WU.WOLF-07 c.2002C>T; p.Q668X c.2002C>T; p.Q668X
WU.WOLF-09 c.376G>A; p.A126T c.1838G>A;p.W613X
WU.WOLF-10 c.376G>A; p.A126T c.1838G>A;p.W613X
WU.WOLF-11 c.376G>A; p.A126T c.1838G>A;p.W613X
WU.WOLF-12 c.320G>A; p.G107E c.1882C>T; p.R629W
WU.WOLF-13 c.599delT; p.L200fs286Stop c.2254G>T; pE752Stop
WU.WOLF-14 c.817G>T; p.E273X c.1839G>A; p.W613X
WU.WOLF-15 c.439delC, p.R147fsX163 c.1620G>A, p.W540X
WU.WOLF-16 c.1240_1242delTTC; p.F414del c.1689_1694delCTTCTT; p.F564del; p.L565del
WU.WOLF-17 c.599T>C; p.L200P c.695G>C; p.R232P
WU.WOLF-18 c.1251_1252delCTinsG; p.Phe417Leufsx25 c.1885C>T; p.Arg629Trp
WU.WOLF-19 c.2339G>C, p.Gly780Ala c.2452C>T, p.Arg818Cys
WU.WOLF-22 c.605A>G; p.E202G c.631G>A; p.D211N
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[24,25]). Vibration sensation was impaired in eight
(44%). Other neurologic deficits included slow motor
movements in three (17%) and increased tone and brisk
deep tendon reflexes in one.
Disorders of olfaction were common (13 subjects =
72%) (Table 5). Four (57%, average age 15.6 years) of the
males has severe microsmia or total anosmia, while one
had normal olfaction at age 7.3 and two others had mild
to moderate defects (ages 14.3 and 11.9). Three (27%,
average age 13.5 years) of the females had severe
microsmia or total anosmia, while four (36%, average age
13.7 years) had normal olfaction and four (36%, average
age 16.5 years) had mild or moderate microsmia.
Verbal IQ was overall very high, with 15 of the 16
tested performing at the average range or above. The
subject with a history of near drowning performed in
the borderline range.
Clinical neuroimaging findings
Three subjects could not undergo MRI neuroimaging due
to medical implants and or anxiety. Thus, scans were
obtained on 14 subjects. Pituitary abnormalities (reduced
or absent bright spot on T1-weighted images or small pos-
terior pituitary) were seen in seven (50%) of the scans. Of
these seven, five had diabetes insipidus, but 6 (67%) of the
subjects who were scanned who had diagnosed diabetes
insipidus did not have an abnormal pituitary. In addition,
T2-weighted or flair imaging showed signal abnormalities
in pons (one, 7%) or cortex (five, 36%).
No other clinically detectable abnormalities were noted.
However, reduced volume of the brainstem and cerebel-
lum have been found compared to age-matched controls
(data previously published [26]).
Vision assessment
Pallor of the optic disc was present in 17 subjects (94%).
The one subject with a normal optic disc, interestingly,
did have a color vision defect, acuity defect and a cataract
(Table 6). Abnormalities in visual acuity and color vision
were present in 17 (94%). Abnormal pupillary response,
nystagmus, and cataracts were present in 11 (61%), five
(28%), and five (28%), respectively. Interestingly, six (33%)
of the subjects noted loss of their color vision around age
6, most long before any vision problems were formally di-
agnosed. In five (27%) of the subjects, school screening or
teachers were the first to identify a vision problem, which
led in some cases to the diagnosis of WFS. The finding of
optic atrophy led to the diagnosis of WFS in seven (39%),
but three (17%) were diagnosed with optic atrophy for 2
to 10 years before the diagnosis of WFS was made.
Audiology findings
Normal hearing was found in four subjects (22%). Pro-
found hearing loss with onset before age 2 was present
Table 3 Hemoglobin A1c and oral glucose tolerance test results
Subject HgbA1c Fasting glucose Fasting C-peptide Glucose at time 30 min C-peptide at time 30 min
WU.WOLF-01 8.1 135 0.1 352 0.4
WU.WOLF-02 8 287 1.0 ND ND
WU.WOLF-03 6.2 190 0.5 205 0.4
WU.WOLF-04 7.5 277 0.1 ND ND
WU.WOLF-05 7.6 91 0.1 283 0.2
WU.WOLF-07 6.7 103 0.1 238 0.3
WU.WOLF-09 11.5 280 0.2 ND ND
WU.WOLF-10 8 167 0.2 305 0.4
WU.WOLF-11 6.6 139 0.9 202 1.8
WU.WOLF-12 6.5 231 0.1 302 0.2
WU.WOLF-13 8.0 ND ND ND ND
WU.WOLF-14 9.3 269 0.5 ND ND
WU.WOLF-15 8.2 167 0.2 265 0.3
WU.WOLF-16 7.7 144 <0.1 194 0.2
WU.WOLF-17 9.3 257 0.2 ND ND
WU.WOLF-18 8.3 267 0.2 ND ND
WU.WOLF-19 5.1 85 2.1 113 9.3
WU.WOLF-22 6.5 184 0.9 266 2.6
MEAN 7.7 192.5 0.5 247.7 1.5
STD 1.4 70.9 0.5 66.4 2.7
ND = Not done.
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in one and one other probably also had very early pro-
found hearing loss as noted above.
With respect to vestibular function, one subject had
reduced gain of the vestibulo-ocular reflex to steps of
angular acceleration and reduced gain and increased
low-frequency phase lead on sinusoidal harmonic testing
over the range 0.025–0.5 Hz. This provides for the first
time quantitative evidence that WS can cause profound
vestibular loss in a subset of subjects.
Urology findings
One subject had chronic renal failure and neurogenic
bladder diagnosed at age 17. Enuresis was reported by
four (22%) and nocturia by three (17%). Of the 11 tested
for bladder emptying, five (45%) had elevated post-void
residual bladder volume.
Discussion
WFS is a rare monogenic disorder characterized by ER
stress in cell lines [4,6,27] and in animal models [4,5,7]
with multiple clinical manifestations. Comprehensive,
standardized phenotyping of subjects in the early stages
of this syndrome is limited. This study identified many
clinically detectable symptoms present in a group of in-
dividuals with WFS in its relatively early stages. These
data contribute to our understanding of the natural his-
tory of the clinical features of this complex syndrome,
which could facilitate diagnosis with WFS and ultimately
be useful in future therapeutic trials.
In many subjects a significant delay occurred between
the time of the diagnosis of the first signs of the syndrome
and the diagnosis of WFS. In some cases the delay led to
prolonged periods of polyuria, vision problems, or hearing
problems before those features were diagnosed and
treated. Primary care physicians, ophthalmologists, and
endocrinologists were all likely to be the caregivers first
proposing the diagnosis and school screening programs
were instrumental in identifying vision and hearing losses
in several. Earlier diagnosis may improve the quality of life
of subjects with WFS by leading to earlier diagnosis and
intervention of all of the features of WFS. Diabetes
insipidus and bladder issues in particular are difficult to




WU.WOLF-01 Increased tone lower
extremities; intention
tremor
Brisk 3+/4 at ankles Normal Mild dysmetria Unable to tandem walk
WU.WOLF-02 Normal Normal Normal Normal Normal









WU.WOLF-05 toe tapping slow Normal Normal Normal Abnormal tandem walk
WU.WOLF-07 Normal Normal Normal Normal Normal
WU.WOLF-09 Normal Normal Impaired vibration (R4/L4) Normal Abnormal tandem walk
WU.WOLF-10 Normal Normal Normal Normal Normal
WU.WOLF-11 Normal Normal Normal Normal Abnormal tandem walk
WU.WOLF-12 Normal Normal Impaired vibration (R2/L2) Normal Abnormal tandem walk
WU.WOLF-13 Normal Normal Normal Normal Normal
WU.WOLF-14 Fine finger
movements slow
Normal Normal Normal Normal
WU.WOLF-15 Normal Normal Normal Normal Normal
WU.WOLF-16 Normal Normal Mildly impaired vibration Mild dysmetria Abnormal tandem walk
WU.WOLF-17 Normal Normal Mildly impaired vibration Some difficulty
hopping
Abnormal tandem walk
WU.WOLF-18 Normal Normal Mildly impaired vibration Normal Mildly abnormal tandem
walk
WU.WOLF-19 Normal Normal Difficult to assess,
probably normal
Normal Normal
WU.WOLF-22 Normal Normal Mildly impaired vibration Normal Normal
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diagnose in a subject with pre-existing diabetes mellitus
given that polyuria and polydipsia are features of both. It
is likely that there are subjects who might be diagnosed
even before the onset of diabetes mellitus or insipidus if
there is an index of suspicion for the disorder in subjects
with hearing loss, color vision defects, gait abnormalities,
etc. We suggest that the addition of certain questions on
review of systems in subjects with diabetes, in particular,
could lead to earlier diagnosis of the syndrome. For ex-
ample, color blindness and loss of olfaction are common,
even in the youngest subjects with WFS, and were fre-
quently noticed by the subjects but not mentioned to
caregivers. Both can be rather easily and inexpensively
screened in an outpatient primary care or endocrinology
clinic setting in the event a patient reports symptoms.
The literature indicates that WFS is a progressive neuro-
degenerative disorder with severe neurologic abnormal-
ities and often death during the third or fourth decade of
life. However, the order in which symptoms emerge over
time in WFS has been difficult to discern. A recent paper
surveying (but not directly assessing) 59 subjects with
WFS ranging in age from 5 to 54 found that some individ-
uals are reported to have optic atrophy prior to the diag-
nosis of diabetes mellitus [17]. These investigators did not
test each subject directly, and did not assess olfaction or
color vision, so it is not clear whether these features were
also present prior to diabetes. Our study indicates that in-
dividuals with WFS may manifest multiple abnormalities
of the sensory (vision, hearing and olfactory), neurologic
and endocrine systems relatively early in the disease
Table 5 Olfaction, verbal IQ, neuroimaging, and audiology testing findings
Subject Test of olfaction Verbal IQ range Clinical neuroimaging
findings
Hearing loss Type of hearing loss
WU.WOLF-01 Total Anosmia ND ND Yes Sensorineural
WU.WOLF-02 Mild Microsmia Very Superior Normal No Normal
WU.WOLF-03 Total Anosmia High Average No pituitary bright spot Yes—hearing aid at age 6 Sensorineural
WU.WOLF-04 Severe Microsmia Average ND Yes—hearing aid at
age 12
Sensorineural
WU.WOLF-05 Normosmia Borderline ND Yes—cochlear implant at
age 2
Sensorineural
WU.WOLF-07 Normosmia High Average Loss of pituitary bright
spot
Yes, on right only—
diagnosed at clinic
Conductive
WU.WOLF-09 Mild Microsmia High Average Elevated T2 in the pons No Normal
WU.WOLF-10 Normosmia Average Several areas of T2
elevation
No Normal
WU.WOLF-11 Total Anosmia High Average Normal Yes—diagnosed at clinic Mixed
WU.WOLF-12 Total Anosmia Average Several small T2
anomalies
Yes—hearing aid at age 7 Sensorineural
WU.WOLF-13 Total Anosmia Average Small posterior pituitary Yes—diagnosed at clinic;
no hearing aids
Sensorineural




WU.WOLF-15 Total Anosmia Superior Faint pituitary bright spot Yes—No hearing aids Sensorineural
WOLF2011-16 Moderate Microsmia High Average Multiple T2 abnormalities,




Yes—No hearing aids Sensorineural
WU.WOLF-17 Mild Microsmia High Average Multiple punctate T2 foci
in frontal lobes. Pituitary
bright spot not seen
Yes—No hearing aids Sensorineural
WU.WOLF-18 Mild Microsmia Very Superior Absent pituitary bright
spot
Yes—hearing aids Sensorineural
WU.WOLF-19 Mild Microsmia ND ND Yes—No hearing aids Sensorineural
WU.WOLF-22 Normosmia Average Several small foci of
elevated flair signal
Yes—Cochlear Implants Sensorineural
ND = testing not done.
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process. In particular, our limited sample suggests that
optic atrophy may not always predate other clinically ap-
parent neurologic findings (i.e. WU.WOLF-19). However,
this study is limited by the small number of subjects eval-
uated and may have a bias toward higher functioning fam-
ilies with the interest and means to attend the clinic.
Future clinics will include a larger number of subjects, but
international cooperation and standard assessment tools,
such as a rating scale for severity (e.g. the Wolfram Uni-
fied Rating Scale or WURS [28]) will be necessary to fully
address this issue. Whether the additional manifestations
we identified predict the long-term course of WFS will re-
quire longitudinal follow-up of this and other cohorts.
Since the majority of subjects with WFS have diabetes
mellitus at the time that WFS is diagnosed, these other
sensory and neurological manifestations may be important
for following the natural history of WFS and testing the
effect of potential interventions.
The WFS1 gene is one of the genes repeatedly shown
to be associated with Type 2 diabetes [29-32], indicating
that WFS may be an unusual example of a Type 2-like
diabetes mellitus of monogenic cause. This characteristic
may present an opportunity for testing diabetes therap-
ies in a monogenic setting or further delineating the
mechanism of disease in Type 2 diabetes. The WFS1
gene encodes for the Wolframin protein that is an ER
membrane protein recently shown to control the degree
of ER stress [4]. A number of neurodegenerative
disorders including Alzheimer’s, Huntington’s, and prion
diseases have also been proposed as disorders of the ER
stress response, suggesting that WFS may also represent
a useful model of much more common neurodegenera-
tive diseases [33]. It is encouraging that therapeutic
agents to treat ER-stress-related diseases are actively be-
ing developed [34].
WFS causes multiple endocrine and neurologic defi-
cits, even early in the course of the disease that are clin-
ically apparent when subjects are directly examined in a
standardized manner. The sensory system appears par-
ticularly affected, with defects found in vision, hearing,
the vestibular system, and olfaction soon after diagnosis
with diabetes. Understanding the evolution of these
symptoms over time in WFS is a necessary step towards
preparing for future clinical trials.
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